Journal: ACS infectious diseases
Article Title: Restoring and enhancing the potency of existing antibiotics against drug-resistant Gram-negative bacteria through the development of potent small-molecule adjuvants
doi: 10.1021/acsinfecdis.2c00121
Figure Lengend Snippet: (A and B) Checkerboard assays showed sensitization of A. baumannii by MD-124 towards rifampicin and novobiocin. (C and D) Checkerboard assays showed sensitization of K. pneumoniae by MD-124 towards rifampicin and clarithromycin. (E) Sensitization of an NDM-1-expressing strain of E. coli by MD-124 towards rifampicin. (F) Sensitization of an mcr-1-expressing strain of E. coli by MD-124 towards rifampicin. (G) Sensitization of MDR K. pneumoniae by MD-124 towards rifampicin. (H) Sensitization of MDR S. Typhimurium by MD-124 towards rifampicin. All experiments were done at least in biologically independent duplicate.
Article Snippet: Escherichia coli (ATCC 25922 or ATCC 10536), Acinetobacter baumannii (ATCC 17978), Klebsiella pneumoniae (ATCC 43816), Stenotrophomonas maltophilia (ATCC 31559), Salmonella enterica Typhimurium (ATCC 14028), Citrobacter werkmanii (ATCC 51114), MDR Klebsiella pneumoniae (ATCC BAA-2472) and MDR Salmonella enterica serovar Typhimurium (ATCC 700408) were also purchased from ATCC.
Techniques: Expressing